-
Etop Pharma's SHP2 allosteric inhibitor approved for clinical trials in China
Time of Update: 2021-08-15
The Center for Drug Evaluation (CDE) of the National Medical Products Administration of China has announced that Etoppharma’s SHP2 allosteric inhibitor ET0038 tablet has obtained two clinical trials implied licenses, and it is planned to be developed for the treatment of advanced solid tumors with abnormal MAPK signaling pathways .
-
Nankai University Science Publication: The activation and allosteric regulation mechanism of the full-length calcium-sensitive receptor CaSR
Time of Update: 2021-08-10
On June 4, 2021, the team of Xue Yang/Yue Shen of Nankai University published an article titled Structural basis for activation and allosteric modulation of full-length calcium-sensing receptor in Science Advances.
-
Nuocheng Jianhua's new SHP2 allosteric inhibitor ICP-189 new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2021-08-05
On July 28, the biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) announced that the company's new protein tyrosine phosphatase SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP -189 New Drug Research (IND) application was accepted by the National Medical Products Administration (NMPA) .
-
Nuocheng Jianhua SHP2 allosteric inhibitor submits clinical application
Time of Update: 2021-08-05
According to the press release, ICP-189 is mainly used to treat a variety of solid tumors.
It aims to provide new solid tumors such as lung cancer, head and neck cancer and gastrointestinal tumors Clinical treatment methods .
-
Yituo Pharmaceutical's SHP2 allosteric inhibitor was approved by the FDA for IND
Time of Update: 2021-06-30
Studies have shown that ET0038 specifically and efficiently inhibits the activity of SHP2 tyrosine phosphatase, and shows highly effective anti-tumor activity in a variety of tumor models that carry oncogenic mutations in the RTK/RAS pathway, including non-small cell lung cancer and pancreatic cancer.
-
Research reveals the binding properties of dopamine receptor D1R and dopamine and its potential allosteric regulation mechanism
Time of Update: 2021-04-28
com/tags/%E5%B8%95%E9%87%91%E6%A3%AE%E6%B0%8F%E7%97%85/">Parkinson's diseasePositive binding ligands such as the endogenous ligand DA and other synthetic agonist drugs targeting D1R activate the receptor through the positive binding pocket that acts on the extracellular region of D1R.
-
Radiolabeled Ligand Binding to the Catalytic or Allosteric Sites of PDE5 and PDE11
Time of Update: 2021-02-27
Phosphodiesterase-5 (PDE5), which is highly specific for guanosine 3′-5′-cyclic-monophosphate (c GMP ) at both its catalytic site and its allosteric sites, has generated particular interest because it is potently and specifically inhibited by three drugs: sildenafil (Viagra™, Pfizer), tadalafil (Cialis™, Lilly-ICOS), and vardenafil (Levitra™, Bayer GSK).
-
Selection In Vitro of Allosteric Ribozymes
Time of Update: 2021-01-07
In this chapter, we describe a procedure known as allosteric selection, in which an RNA catalyst in conjunction with a random sequence domain is subjected to iterative in vitro selection in order selectively to recover ligand-dependent ribozymes.
-
Selecting Allosteric Ribozymes
Time of Update: 2020-12-12
Allosteric ribozymes can be designed to respond to virtually any molecule of choice.
The present protocol describes an in vitro selection strategy for the de novo selection of allosteric self-cleaving ribozymes responding to virtually any drug of choice.
-
Zhou Lu research group and its collaborators of Fudan University School of pharmacy found a new allosteric inhibitor of pgam1
Time of Update: 2019-10-19
Recently, Zhou Lu Group, School of medicine, Fudan University, together with Shen Ying group, School of medicine, Shanghai Jiaotong University and Chen Hongzhuan group, Shanghai University of traditio